<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01058759</url>
  </required_header>
  <id_info>
    <org_study_id>ENOXA-NSCLC</org_study_id>
    <nct_id>NCT01058759</nct_id>
  </id_info>
  <brief_title>Taxotere-Enoxaparin-(ENOXA)-Study</brief_title>
  <official_title>Taxotere-Enoxaparin-(ENOXA)-Study: 1st-Line Docetaxel-Platin Chemotherapy as Single Therapy or in Combination With Enoxaparin in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, a Phase III Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hannover Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Taxotere-Enoxaparin-(ENOXA)-Study: 1st-Line Docetaxel-Platin Chemotherapy as single therapy&#xD;
      or in combination with Enoxaparin in patients aged older than 18 years with locally advanced&#xD;
      or metastatic non-small cell lung cancer (stadium IIIb/IV), a phase III study. Study&#xD;
      hypothesis: Increase of progressive free survival from 5 to 7.5 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The external funding (pharmaceutical company) was stopped and could not be substituded by&#xD;
    internal funding.&#xD;
  </why_stopped>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progressive free survival</measure>
    <time_frame>monthly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RECIST</measure>
    <time_frame>monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>every three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>thromboembolic complications</measure>
    <time_frame>monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety of long term application of Enoxaparin</measure>
    <time_frame>monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall toxicity</measure>
    <time_frame>monthly</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm B: Enoxaparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A: No Enoxaparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <arm_group_label>Arm B: Enoxaparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Enoxaparin</intervention_name>
    <arm_group_label>Arm A: No Enoxaparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Men and women aged 18 and older&#xD;
&#xD;
          -  Locally Advanced or Metastatic Non-small Cell Lung Cancer stage IIIB/IV without any&#xD;
             previous therapy&#xD;
&#xD;
          -  Life expectancy at least 12 weeks&#xD;
&#xD;
          -  EOCG performance &lt; 1&#xD;
&#xD;
          -  Appropriate renal and hepatic function&#xD;
&#xD;
          -  Appropriate Hematology&#xD;
&#xD;
          -  No bleeding events within 4 weeks prior to randomization&#xD;
&#xD;
          -  No indication for prophylactic or therapeutic anticoagulation therapy&#xD;
&#xD;
          -  Appropriate methods of contraception (both: men and women) for women of childbearing&#xD;
             potential negative urine pregnancy test within 7 day prior to randomization&#xD;
&#xD;
          -  Capability for s.c. injection of Enoxaparin every 24 hrs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of cancer other than NSCLC&#xD;
&#xD;
          -  Known contraindication for Enoxaparin e.g. HIT,&#xD;
&#xD;
          -  Known contraindication for Docetaxel, Cisplatin, Carboplatin or co-medication&#xD;
&#xD;
          -  Participation in any other clinical trials within 30 days prior to randomization&#xD;
&#xD;
          -  Any known medical condition that does not allow therapy according to study protocol&#xD;
&#xD;
          -  Seizure disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Dickgreber, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hannover Medical School, Department of Pneumology</name>
      <address>
        <city>Hannover</city>
        <state>Lower Saxonia</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>January 28, 2010</study_first_submitted>
  <study_first_submitted_qc>January 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2010</study_first_posted>
  <last_update_submitted>August 21, 2018</last_update_submitted>
  <last_update_submitted_qc>August 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Enoxaparin</keyword>
  <keyword>Locally Advanced or Metastatic Non-small Cell Lung Cancer stadium IIIb/IV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
    <mesh_term>Enoxaparin sodium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

